ActiveSite
ActiveSite is a company.
Active
Updated: ·
About
ActiveSite is a company.
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at ActiveSite.
ActiveSite is a company.
ActiveSite is a company.
Key people at ActiveSite.
ActiveSite Pharmaceuticals, Inc. is a biopharmaceutical company developing small molecule drugs targeting proteases for diseases in the nervous system, cardiovascular, and eye domains, with a preclinical pipeline focused on conditions like ischemic stroke, diabetic macular edema, and macular edema.[2][3] It serves patients and healthcare providers by addressing unmet needs in these areas through proprietary lead discovery technology that identifies novel protease inhibitors, currently advancing candidates such as ASP-PDC-010, ASP-PDC-030, ASP-PDC-020, and RZ-402, all at the preclinical stage as of late 2025.[3]
The company demonstrates early research momentum via partnerships, including a license and development agreement with AntriaBio for plasma kallikrein inhibitors and another development and license deal documented in SEC filings, highlighting its strategy to monetize intellectual property while progressing its protease-focused platform.[4][5]
ActiveSite Pharmaceuticals emerged from expertise in protease-targeted drug discovery, utilizing proprietary technology to identify small molecule candidates for challenging therapeutic areas like nervous system diseases.[2][4] Key figures associated with the company include scientists such as Edward P. Feener, Tamie J. Chilcote, Sukanto Sinha, Allen C. Clermont, Sven-Erik Bursell, and Joanna A. Phipps, who contribute to its focus on cardiovascular, eye, and neurological disorders.[2]
Pivotal early moments include licensing deals, such as the agreement with AntriaBio announced for plasma kallikrein inhibitors, leveraging ActiveSite's IP platform, and a formal development and license pact noted in 2017 SEC documents, which validated its technology and supported pipeline progression.[4][5] These steps mark its evolution from discovery-focused biotech to one pursuing clinical translation.
ActiveSite rides the wave of precision protease inhibition in biotech, a trend gaining traction amid advances in understanding protease roles in neurodegeneration, vascular damage, and retinal disorders, amplified by AI-driven drug discovery tools as of 2025.[2][3] Timing aligns with rising demand for small molecule therapies in CNS and ophthalmology, where biologics face delivery challenges, and market forces like aging populations boost needs for stroke and macular edema treatments.
By licensing IP to partners like AntriaBio, ActiveSite influences the ecosystem through technology transfer, accelerating industry-wide development of kallikrein and related inhibitors while conserving resources for its core pipeline.[4] This positions it as an enabler in the preclinical biotech segment, contributing to broader efforts in orphan and high-burden diseases.
ActiveSite's next milestones likely involve advancing its preclinical assets—ASP-PDC-010 for diabetic macular edema, ASP-PDC-030 for ischemic stroke, and others—toward IND-enabling studies, potentially via additional partnerships to fund Phase 1 entry.[3] Trends like AI-enhanced protease modeling and combo therapies for neurovascular diseases will shape its path, with small molecules offering advantages in blood-brain barrier penetration.
Its influence may grow through expanded licensing, evolving from pure discovery to a platform licensor, mirroring successful biotechs that thrive on IP without full clinical risk, ultimately delivering targeted therapies to underserved patients.
Key people at ActiveSite.